Any current/future new fundraising through debt or equity?

No specific mention of any current or planned new fundraising through debt or equity in the provided transcript. The management highlighted that the company's gearing ratio is well under control at around 0.47 (47% of equity). Debt Coverage Ratio (DCR) remains comfortable, with committed revenue repayments planned for the coming year based on last year's performance and expected similar growth. There is no indication from the call that the company intends to raise new funds via debt or equity in the near future. Focus is on managing existing debt prudently while pursuing growth through operati

Any current/future capex/capital investment/strategic investment?

ZIM Laboratories is investing continuously in upgrading facilities, infrastructure, and systems, especially in response to EU-GMP inspection observations related to manual documentation (Page 16). They plan to implement electronic data handling systems and automation to address critical observations (Page 6). No extra or standout budget is required specifically for these CAPA-related upgrades as the investments are part of their existing annual facility and infrastructure enhancement plans (Page 16). The company is also investing in R&D with INR79 million allocated in Q1 FY '26, focusing on pr

Future growth expectations in sales/revenue/volumes?

Growth in base business and NIP (New Innovative Products) outside EU, particularly in Rest of World (RoW) and emerging markets, is expected to be strong. Base business revenue is anticipated to start picking up from Q2 FY '26, with exact guidance expected post H1. EU market revenue upside is delayed by 3-6 months; commercialization in EU to likely start in FY '26 last two quarters. Revenue target remains similar to previous year (around INR 380-390 crores), excluding deferred EU revenues. Licensing milestones and revenues from NIP and OTF products are progressing steadily. The compan

Future growth expectations in earnings/operating earnings/profits/EPS?

Base business expected to continue growth similar to previous year; no impact from EU-GMP issue on base revenue (Page 19, 18, 6). EU market revenue upside postponed to next financial year, likely delaying significant growth from NIP products in Europe until FY27 or later (Page 19, 9). Operating leverage expected to normalize and improve over next 2 quarters as supply and geopolitical issues ease (Page 9). EBITDA margin around 7.9% in Q1 with some pressure due to challenges; potential margin improvement with stable or growing base business (Page 5). R&D spend to continue at similar ratio; no co

Current/ Expected Orderbook/ Pending Orders?

The transcripts do not explicitly mention the current or expected order book or pending orders in exact figures. Management indicated the EU sales and associated business have been postponed or shifted due to regulatory inspection delays, pushing expected EU upside to the next financial year. Strong signals of growth and ongoing supply in the Rest of World (RoW) markets and emerging markets continue. The Middle East business accounts for about 30% of current revenues and is expected to stabilize and improve in the next two quarters. Partnership in UAE with global pharma has led to filing of ar

Zim Laboratories LtdQ2 FY26Pharmaceuticals & Biotechnology

Zim Laboratories Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹110P/E: 141.2Market Cap: ₹614 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Growth in base business and NIP (New Innovative Products) outside EU, particularly in Rest of World (RoW) and emerging markets, is expected to be strong.
→Base business revenue is anticipated to start picking up from Q2 FY '26, with exact guidance expected post H1.
→EU market revenue upside is delayed by 3-6 months; commercialization in EU to likely start in FY '26 last two quarters.
→Revenue target remains similar to previous year (around INR 380-390 crores), excluding deferred EU revenues.
→Licensing milestones and revenues from NIP and OTF products are progressing steadily.
→The company is confident about regaining EU-GMP certification within 6 to 9 months, enabling EU market entry afterwards.
→Supply disruptions in Middle East have eased, and recovery in that market is expected in next 1-2 quarters.
→Overall, diversified markets, ongoing partnerships, and innovation pipeline support optimistic medium-term growth outlook.

Margin guidance

Category 3

→Base business expected to continue growth similar to previous year; no impact from EU-GMP issue on base revenue (Page 19, 18, 6).
→EU market revenue upside postponed to next financial year, likely delaying significant growth from NIP products in Europe until FY27 or later (Page 19, 9).
→Operating leverage expected to normalize and improve over next 2 quarters as supply and geopolitical issues ease (Page 9).
→EBITDA margin around 7.9% in Q1 with some pressure due to challenges; potential margin improvement with stable or growing base business (Page 5).
→R&D spend to continue at similar ratio; no cost reductions expected due to regulatory delays (Page 6).
→PAT expected to return to profitability post resolution of EU-GMP CAPA and improved sales in EU and RoW markets (inferred from discussions on phased recovery and growth).
→Overall optimistic long-term outlook contingent on CAPA completion, reinspection in 6-9 months, and partner launches in FY26-FY27 (Pages 20, 13, 9).

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any current or planned new fundraising through debt or equity in the provided transcript.
→The management highlighted that the company's gearing ratio is well under control at around 0.47 (47% of equity).
→Debt Coverage Ratio (DCR) remains comfortable, with committed revenue repayments planned for the coming year based on last year's performance and expected similar growth.
→There is no indication from the call that the company intends to raise new funds via debt or equity in the near future.
→Focus is on managing existing debt prudently while pursuing growth through operations and product development.

Order book

→The transcripts do not explicitly mention the current or expected order book or pending orders in exact figures.
→Management indicated the EU sales and associated business have been postponed or shifted due to regulatory inspection delays, pushing expected EU upside to the next financial year.
→Strong signals of growth and ongoing supply in the Rest of World (RoW) markets and emerging markets continue.
→The Middle East business accounts for about 30% of current revenues and is expected to stabilize and improve in the next two quarters.
→Partnership in UAE with global pharma has led to filing of around five products and receipt of first orders expected to complete in Q2.
→Licensing milestone payments from innovative product agreements stood at INR 48 million in Q1, indicating ongoing business.
→Overall, orderbook in regulated markets like EU has been affected due to inspection delays, but other markets have steady or growing demand.

Capex plans

Yes

→ZIM Laboratories is investing continuously in upgrading facilities, infrastructure, and systems, especially in response to EU-GMP inspection observations related to manual documentation (Page 16).
→They plan to implement electronic data handling systems and automation to address critical observations (Page 6).
→No extra or standout budget is required specifically for these CAPA-related upgrades as the investments are part of their existing annual facility and infrastructure enhancement plans (Page 16).
→The company is also investing in R&D with INR79 million allocated in Q1 FY '26, focusing on product development, dossier upgrades, infrastructure, and Bioequivalence studies for innovative product pipeline (Page 5).
→Focused strategic investments continue in strengthening presence in Rest of World (RoW) and emerging countries despite challenges in the EU market (Page 5).
→No mention of new large-scale or future capex beyond ongoing upgrades and R&D spend.

How does Zim Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Zim Laboratories Ltd

Rev 4Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Zim Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio